serotonin). The 5-HT1B receptor (5-HT1BR) is a Gi class G protein-coupled receptor, and it is a target for the treatment of migraine, depression, anxiety and other diseases related to serotonergic neurotransmission. Triptans have replaced ergotamines in clinical usage and are currently the first-line antimigraine therapy for attacks of moderate to severe intensity. In this study, a series of novel tryptamine
偏头痛是一种普遍的致残性原发性头痛疾病,伴随着内源性 5-羟
色胺(5-HT;5-羟
色胺)的特征性消耗。5-HT 1B受体 (5-HT 1B R) 是 Gi 类 G 蛋白偶联受体,是治疗偏头痛、抑郁症、焦虑症和其他与 5-羟
色胺能神经传递相关疾病的靶点。曲坦类药物已在临床使用中取代麦角
胺类药物,目前是中度至重度发作的一线
抗偏头痛药物。本研究基于 FDA 批准的曲坦类与 5-HT 1B R的结合模式,通过分子对接设计了一系列新型
色胺衍
生物,合成并评估了 5-HT 1BR激活。在所检查的化合物中,6k (
EC 50 =8.57 nM;K i =16.56 nM)、6f (
EC 50 =10.77 nM;K i =36.95 nM)和6m (
EC 50 =24.32 nM;K i =22.20 nM)发现比 FDA 批准的药物
舒马曲坦 (
EC 50 =37.71 nM;K i =130.62 nM)是更有效的